Aldosterone receptor antagonists for heart failure: current status, future indications.
Many patients with heart failure should receive an aldosterone receptor antagonist, ie, either spironolactone (Aldactone) or the newer agent eplerenone (Inspra)--in addition to an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB) or both, and a beta-blocker. We review the evidence and indications.
University of Michigan School of Medicine, Ann Arbor, MI, USA.
Bertram
B
Pitt
Sanjay
S
Rajagopalan
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000077545:Eplerenone; D005544:Forecasting; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D013148:Spironolactone / Q000031:analogs & derivatives / Q000627:therapeutic use
D000806:Angiotensin-Converting Enzyme Inhibitors; D000451:Mineralocorticoid Receptor Antagonists; D013148:Spironolactone; D000077545:Eplerenone